Payment overview · 2025
General Payments
$24.15
1 reported records · 1 companies
Healthcare provider profile · identity verified
Ellen Mcstravick, AGNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Gerontology · BUFFALO, NY · NPI 1083220677
Verified facts
What the public records show
CMS Open Payments records show Ellen Mcstravick, AGNP-C received $24.15 in general payments during 2025 across 1 reported records.
Edwards Lifesciences Corporation accounted for 100.0% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $24.15 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $24.15 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 230 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 230 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 23 |
| Gabapentin | Gabapentin | 163 | 19 |
| Sertraline Hcl | Sertraline Hcl | 142 | 21 |
| Furosemide | Furosemide | 126 | 20 |
| Lisinopril | Lisinopril | 125 | 23 |
| Eliquis | Apixaban | 114 | 21 |
| Metformin Hcl | Metformin Hcl | 111 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 12 |
| Trazodone Hcl | Trazodone Hcl | 82 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 81 | 15 |
| Famotidine | Famotidine | 79 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 21 |
| Losartan Potassium | Losartan Potassium | 63 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | suppressed |
| Rezvoglar Kwikpen | Insulin Glargine-Aglr | 59 | 14 |
| Baclofen | Baclofen | 57 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | suppressed |
| Prednisone | Prednisone | 51 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Carvedilol | Carvedilol | 46 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 44 | 13 |
| Midodrine Hcl | Midodrine Hcl | 43 | suppressed |
| Trulicity | Dulaglutide | 43 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 40 | suppressed |
| Nystatin | Nystatin | 38 | 13 |
| Spironolactone | Spironolactone | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 19 |
| Torsemide | Torsemide | 35 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | suppressed |
| Latanoprost | Latanoprost | 30 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Scopolamine | Scopolamine | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Mirabegron Er | Mirabegron | 23 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Alogliptin | Alogliptin Benzoate | 21 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 19 |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 17 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Loxapine | Loxapine Succinate | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Desloratadine | Desloratadine | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Acetazolamide Er | Acetazolamide | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $24.15 · 1 records | Edwards Lifesciences Corporation | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error